| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 2001 | 2020 |
| Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients LV Beerepoot, N Mehra, JSP Vermaat, BA Zonnenberg, M Gebbink, ... Annals of oncology 15 (1), 139-145, 2004 | 327 | 2004 |
| Abiraterone and olaparib for metastatic castration-resistant prostate cancer NW Clarke, AJ Armstrong, A Thiery-Vuillemin, M Oya, N Shore, E Loredo, ... NEJM evidence 1 (9), EVIDoa2200043, 2022 | 297 | 2022 |
| Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial JS de Bono, N Mehra, GV Scagliotti, E Castro, T Dorff, A Stirling, A Stenzl, ... The Lancet Oncology 22 (9), 1250-1264, 2021 | 237 | 2021 |
| The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs DL van der Velden, LR Hoes, H Van Der Wijngaart, ... Nature 574 (7776), 127-131, 2019 | 234 | 2019 |
| The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact LF van Dessel, J van Riet, M Smits, Y Zhu, P Hamberg, ... Nature communications 10 (1), 5251, 2019 | 190 | 2019 |
| Lactate dehydrogenase: a marker of diminished antitumor immunity S Van Wilpe, R Koornstra, M Den Brok, JW De Groot, C Blank, J De Vries, ... Oncoimmunology 9 (1), 1731942, 2020 | 159 | 2020 |
| Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer N Mehra, M Penning, J Maas, N van Daal, RH Giles, EE Voest Clinical cancer research 13 (2), 421-426, 2007 | 150 | 2007 |
| Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases N Mehra, M Penning, J Maas, LV Beerepoot, N van Daal, CH van Gils, ... Clinical Cancer Research 12 (16), 4859-4866, 2006 | 127 | 2006 |
| Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a … F Saad, NW Clarke, M Oya, N Shore, G Procopio, JD Guedes, C Arslan, ... The Lancet Oncology 24 (10), 1094-1108, 2023 | 125 | 2023 |
| Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA) N Mehra, D Dolling, S Sumanasuriya, R Christova, L Pope, S Carreira, ... European urology 74 (3), 283-291, 2018 | 120 | 2018 |
| Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis MB Lambros, G Seed, S Sumanasuriya, V Gil, M Crespo, M Fontes, ... Clinical Cancer Research 24 (22), 5635-5644, 2018 | 119 | 2018 |
| PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR … M Hussain, J Mateo, K Fizazi, F Saad, ND Shore, S Sandhu, KN Chi, ... Annals of Oncology 30, v881-v882, 2019 | 114 | 2019 |
| Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer H Westdorp, JHA Creemers, IM van Oort, G Schreibelt, MAJ Gorris, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 104 | 2019 |
| Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations S Schmid, A Omlin, C Higano, C Sweeney, NM Chanza, N Mehra, ... JAMA network open 3 (10), e2021692-e2021692, 2020 | 98 | 2020 |
| Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European journal of cancer 185, 178-215, 2023 | 92 | 2023 |
| PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant … F Saad, AJ Armstrong, A Thiery-Vuillemin, M Oya, E Loredo, G Procopio, ... Journal of Clinical Oncology 40 (6_suppl), 11-11, 2022 | 92 | 2022 |
| Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer P Rescigno, D Lorente, D Bianchini, R Ferraldeschi, MP Kolinsky, ... European urology 70 (5), 724-731, 2016 | 91 | 2016 |
| Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European urology 83 (3), 267-293, 2023 | 88 | 2023 |
| Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study BM Privé, SMB Peters, CHJ Muselaers, IM van Oort, MJR Janssen, ... Clinical Cancer Research 27 (13), 3595-3601, 2021 | 85 | 2021 |
